This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Overcoming Resistance and Tumor Heterogeneity in Small-Cell Lung Cancer by Targeting DLL3 to Unlock New Therapeutic Opportunities

Overcoming Resistance and Tumor Heterogeneity in Small-Cell Lung Cancer by Targeting DLL3 to Unlock New Therapeutic Opportunities

12:00 pm - Thursday 23rd July 2026

Exploring novel treatment strategies for a historically difficult-to-treat cancer
Leveraging multiple therapeutic modalities, from ADCs to TRPs, to target DLL3
Unlocking potential for better patient outcomes despite tumor heterogeneity and therapy resistance

Speakers:

Julian Rees

Chief Executive Officer & Co-Founder

HOPO Therapeutics